Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Avadomide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN known ✓ | Q96SW2 | 20/20 | 0.98 |
| ▸ | DDB1 known ✓ | Q16531 | 19/20 | 0.98 |
| ▸ | IKZF3 | Q9UKT9 | 6/20 | 0.98 |
| ▸ | TNF | P01375 | 3/20 | 0.98 |
| ▸ | IL1B | P01584 | 3/20 | 0.98 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Avadomide SCHEMBL29520051 | 1.00 | CRBN (0.98) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL15515920 | 1.00 | CRBN (0.98) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL29519996 | 1.00 | CRBN (0.98) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL15120730 | 0.99 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL29442249 | 0.99 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL634577 | 0.99 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL29359950 | 0.99 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL282749 | 0.99 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL20495583 | 0.94 | CRBN (0.90) | CRBNDDB1IKZF3TNFIL1B | |
| Avadomide SCHEMBL20495228 | 0.94 | CRBN (0.90) | CRBNDDB1IKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2991976-B1 | SYNTHESIS OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL) PIPERIDINE-2,6-DIONE | CELGENE CORP (US) | 2017-09-20 | — | — | EP | claimed |
| US-9474757-B2 | Methods for treating cancer using TOR kinase inhibitor combination therapy | SIGNAL PHARMACEUTICALS, LLC (US) | 2016-10-25 | — | — | US | claimed |
| EP-2991976-A1 | SYNTHESIS OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL) PIPERIDINE-2,6-DIONE | Celgene Corporation (US) | 2016-03-09 | — | — | EP | claimed |
| EP-2986322-A1 | COMBINATION THERAPY COMPRISING A TOR KINASE INHIBITOR AND A 5-SUBSTITUTED QUINAZOLINONE COMPOUND FOR TREATING CANCER | Signal Pharmaceuticals, LLC (US) | 2016-02-24 | — | — | EP | claimed |
| EP-2683384-B1 | METHODS OF TREATING CANCER USING 3-(5-AMINO-2-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE | CELGENE CORP (US) | 2015-12-09 | — | — | EP | claimed |
| US-20150274694-A1 | SYNTHESIS OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL)PIPERIDINE-2,6-DIONE | CELGENE CORP (US) | 2015-10-01 | — | — | US | claimed |
| US-9067912-B2 | Synthesis of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,8-dione | CELGENE CORPORATION (US) | 2015-06-30 | — | — | US | claimed |
| US-8906932-B2 | Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4Hquinazolin-3-yl)-piperidine-2,6-dione | CELGENE CORPORATION (US) | 2014-12-09 | — | — | US | claimed |
| WO-2014179416-A1 | SYNTHESIS OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL) PIPERIDINE-2,6-DIONE | CELGENE CORPORATION (US) | 2014-11-06 | — | — | WO | claimed |
| US-20140330016-A1 | SYNTHESIS OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL)PIPERIDINE-2,6-DIONE | CELGENE CORPORATION (US) | 2014-11-06 | — | — | US | claimed |
| WO-2014172436-A1 | COMBINATION THERAPY COMPRISING A TOR KINASE INHIBITOR AND A 5-SUBSTITUTED QUINAZOLINONE COMPOUND FOR TREATING CANCER | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-10-23 | — | — | WO | claimed |
| US-20140314753-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | SIGNAL PHARMACEUTICALS, LLC. (US) | 2014-10-23 | — | — | US | claimed |
| US-20120230983-A1 | METHODS OF TREATING CANCER USING 3-(5-AMINO-2-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE | CELGENE CORPORATION | 2012-09-13 | — | — | US | claimed |
| EP-3925609-B1 | METHODS OF TREATING MULTIPLE MYELOMA WITH IMMUNOMODULATORY COMPOUNDS IN COMBINATION WITH ANTIBODIES | CELGENE CORP (US) | 2025-07-30 | — | — | EP | disclosed |
| EP-3925609-A1 | METHODS OF TREATING MULTIPLE MYELOMA WITH IMMUNOMODULATORY COMPOUNDS IN COMBINATION WITH ANTIBODIES | Celgene Corporation (US) | 2021-12-22 | — | — | EP | disclosed |
| US-20180305333-A1 | SOLID FORMS OF 3-(5-AMINO-2-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE, AND THEIR PHARMACEUTICAL COMPOSITIONS AND USES | CELGENE CORP (US) | 2018-10-25 | — | — | US | disclosed |
| WO-2014100748-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| EP-2683708-A1 | SOLID FORMS OF 3-(5-AMINO-2-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE, AND THEIR PHARMACEUTICAL COMPOSITIONS AND USES | Celgene Corporation (US) | 2014-01-15 | — | — | EP | disclosed |
| WO-2012125438-A1 | SOLID FORMS OF 3-(5-AMINO-2METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE, AND THEIR PHARMACEUTICAL COMPOSITIONS AND USES | CELGENE CORPORATION (US) | 2012-09-20 | — | — | WO | disclosed |
| US-20120232100-A1 | SOLID FORMS OF 3-(5-AMINO-2-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE, AND THEIR PHARMACEUTICAL COMPOSITIONS AND USES | CELGENE CORPORATION | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140330016-A1 | SYNTHESIS OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL)PIPERIDINE-2,6-DIONE | AZI2, DHPS, PKD2 | CRBN 1775/4885DDB1 3918/4885IKZF3 1900/4885 |
| US-20150274694-A1 | SYNTHESIS OF 3-(5-AMINO-2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL)PIPERIDINE-2,6-DIONE | AZI2, DHPS, PKD2 | CRBN 1775/4885DDB1 3918/4885IKZF3 1900/4885 |
| US-20140314753-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | MTOR, CHEK2, ULK1 | CRBN 1790/4885DDB1 491/4885IKZF3 3439/4885 |
| US-20180305333-A1 | SOLID FORMS OF 3-(5-AMINO-2-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE, AND THEIR PHARMACEUTICAL COMPOSITIONS AND USES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ALPP, DPYD | CRBN 903/4885DDB1 2595/4885IKZF3 3437/4885 |
| US-20120232100-A1 | SOLID FORMS OF 3-(5-AMINO-2-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE, AND THEIR PHARMACEUTICAL COMPOSITIONS AND USES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ALPP, DPYD | CRBN 785/4885DDB1 2493/4885IKZF3 3449/4885 |
| US-20120230983-A1 | METHODS OF TREATING CANCER USING 3-(5-AMINO-2-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE | VHL, TP53, MGMT | CRBN 1487/4885DDB1 593/4885IKZF3 2351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.